Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Tubulis GmbH
Study ID
NCT07806773
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TUB-040 — DRUG
    Administered IV

Study Details

The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer (NSCLC). The primary objectives of this study are to determine the safety and tolerability and effectiveness of TUB-040, and/or recommended Phase 2 dose (RP2D).

Key Dates

First listed
Sep 8, 2026
Start date
Nov 30, 2026
Status verified
Sep 2026
Primary completion
May 31, 2029
Completion
May 31, 2029

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NSCLC Dose 1
    Participants will receive TUB-040 administered as an intravenous (IV) infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent.
  • Experimental: NSCLC Dose 2
    Participants will receive TUB-040 administered as an IV infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent.

Primary Outcome Measure

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: From enrollment until 30 days after last dose of study drug ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
START Los AngelesLos AngelesCalifornia90025
START Los Angeles
[email protected]
START New JerseyEast BrunswickNew Jersey08816
START New Jersey
[email protected]

Find similar trials in Los Angeles, CA

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials
By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
START Los Angeles· Los Angeles, CASTART New Jersey· East Brunswick, NJ

Related Studies